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Increased Cyclosporine Uptake by Cells Pretreated with FK506 and 
Evidence for Binding of Both Drugs to a Common Intracellular Protein 
A. Sanghvi. V.S. Warty. W.F. Diven. S. Todo. and T. Starzl 
FK506 is a newly described potent immunosuppressive 
agent. In vitro immunologic studies have indicated a syner-
gism between FKS06 and cyclosporine. Our studies have 
indicated that the cellular uptake of cyclosporine is enhanced 
by pretreatment of peripheral blood Iymphcoytes for 2 to 22 
hours with FKS06. Maximum enhancement of cyclosporin 
uptake was observed in the presence of cquimolar concentra-
tions of both drugs. Equivalent enhancement was observed 
with peripheral blood lymphocytes that were freshly isolated 
or stimulated with phytohemagglutinin. This observation 
may offer an explanation for the observed immunologic 
synergism when both drugs arc coadministered. Also. uptake 
and binding characteristics of FKS06 were evaluated in 
human peripheral blood lymphocytes. The saturating con-
centration of FK506 in these experiments was found to be 
approxImately 0.5 /lM. Scatchard analysis of binding data 
indicated two binding sites with ~ - 3.9 ± 1.8 x IQ-'M 
(high affinity) and K.. - 5.2 ± 0.8 x IQ-'M (low affinity). 
After incubations of cells with cyclosporine and FKS06. cells 
were disrupted by sonication and cell contents were analyzed 
on a Bio-Gel P-60 molecular sieve column. The elution 
profile indicated that both drugs migrated with an intracellu-
lar protein with an approximate molecular weight of 18.000 
to 19.000 dalton. These data imply that the intracellular 
transport of these drugs may involve similar. if not identical. 
proteins. 
Several studies have indicated that FKS06. a novel com-
pound. is a potent immunosuppressive agent. Recent in vitro 
studies have suggested that FK506 possesses immunosup-
pressIve properties similar to those of cyclosporine A. imply-
ing that the mechanisms of action of these two drugs may be 
similar as well. The immunosuppressive effect of FK506 is 
several hundredfold greater than that of cyclosporine A. I •1 As 
previously demonstrated for cyclosporine A. the inhibitory 
effect of FKS06 is seen in mixed leukocyte culture (MLC) 
and on secondary proliferation of allorcactive T cells har-
vested from MLC or propagated from organ transplant 
biopsies.J The published data further show that immunosup-
pression by FKS06 may be mediated through an inhibition of 
interleukin-2 release.1- J again emphasizing the similarities 
between cyclosporm A and FK506. 
AIMS 
We attempted to (1) study the kinetics of binding and uptake 
of FK506 bv the human penpheral blood lymphocytes. (2) 
invcstlgate ;nd characterize the intracellular binding of both 
drugs. and (3) evaluate CsA uptake by human perIpheral 
blood lymphocytes pretreated with FK506. 
MATERIALS AND METHODS 
Tritiated CsA (Sandoz Pharmaceuticals. NY) and FKS06 
(Fujisawa. Japan) were used as ethanolic solutions. Culture 
media and antibiotics were obtained from Glaco (Grand 
Island. NY). Bio-Gel P·6 and P-60 were obtained from 
Bic-Rad (Richmond. CAl. All other reagents and supplies 
came from Fisher Scientific (Pittsburgh, PAl. 
Peripheral blood mononuclear cells were isolated as 
described previously.· Monocytes were removed by means of 
an adhering technique. Lymphocytes were harvested. 
washed twice with ice-cold saline. and then resuspended in 
culture medium. Both the CsA and FKS06 then were added 
to the cell suspension. and cells were incubated for I hour at 
37°C in a himidified mixture of 95% O2:5% CO2, Transport 
fluxes were stopped by adding 10 vol cold saline. Cells were 
washed twice with same cold saline to remove the excess of 
both drugs. The cell pellet was resuspended in ice-cold Tris 
buffer (20 mM. pH 7.2) containing 2-mercaptoetbanol and 
sodium azide. 
The cells were disrupted by sonic oscillations. and cell 
debris was removed by means of centrifugation (40.000 g for 
IS min). A l-mL supernatant sample was centrifuged on a 
mini Bio-Gel P-6 column to separate protein-ligand complex 
from the free ligand that is completely retained in the 
column. The intracellular protein-CsA and FKS06 complex 
then was chromatographed on a Bio-Gel P-60 column (pre· 
calibrated with the appropriate molecular weight protein 
markers). and the fractions were used to determine CsA and 
FKS06 for protein contents. 
Lymphocytes were incubated with different concentra-
tions of FKS06 for I hour at noc. Cells were washed three 
times with cold saline and incubated in 0.2 mL in KOH for I 
hour at 70°C. The digested solution was used for the 
measurement of FK506 by means of enzyme immunoassay 
and protein concentration. 
In another set of experiments. cells were incubated in 1 % 
BSA-RPMI 1640 medium in the presence of I /lg/mL 
FKS06 under culture conditions. Cells were washed and 
exposed to different concentrations of CsA and FKS06 for 2 
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hours. Uptake of CsA by the cells under these conditions was 
evaluated by a measure of radioactivity. 
RESULTS 
The concentration dependence of intracellular accumulation 
and binding of FKS06 by human peripheral blood lympho-
cytes were studied. Cells were incubated in different concen-
trations of FK506 for 1 hour at 37°C. The uptake of FK506 
by PBl was seen as a saturable process. with saturation 
occurring at approximately 0.5 ~M concentration of the drug 
(Fig I). Scatchard analysis of the binding data was consis-
tent with two distinct classes of binding sites. one with I<.! -
3.9 ± 1.8 x 1O-'M for the high-affinity sites and the second 
with I<.! - 5.2 ± 0.8 x 1O-6M for the low-affinity sites. This 
analysis further revealed that there arc 5.6 :t 1.0 x 10· and 
2.5 ± 0.9 x 106 high- and low-affinity binding sites. respec-
tively. per cell. 
In another set of experiments. peripheral blood lympho-
cytes (100 x 106 ) were incubated with 2 ~g FK506 and 1.5 
Ilg CsA in culture medium for 1 hour. Intracellular contents 
were analyzed for binding of both drugs to macromolecules. 
Intracellular accumulation of both drugs was rapid. and both 
appeared specifically associated with intracellular macro-
molecule(s). Figure 2 illustrates the elution profile of both 
cyclosporin and FK506 on a calibrated Bio Gel P-60 column. 
The calibration curve of the molecular-weight markers-
ovalbumin. carbonic anhydrase. cytochrome C. and vitamin 
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FIG 2. 
Bl2_is shown as an inset. These data show that both 
cyclosporine A (lI.) and FK506 (e) elute association with 
protein or proteins with a molecular weight of about 18.000-
19.000 dalton. 
Figure 3 shows the effects of including equivalent amounts 
of either FK or cold CsA (1: I. wt/wt) together with [lHJ 
CsA at each point in the incubation medium on the cellular 
uptake of [lHJ CsA (panel A). For panels Band C. the 
experimental conditions were identical to those in panel A 
except that cells were preincubated for 24 hours with 10 Ilg 
FK/ml (panel C). Subsequently. the cells were washed and 
incubated with [lH] CsA as described above. Under all three 
conditions. the cellular uptake of [JHJ CsA was higher at 
each concentration of eH] CsA in the incubation in the 
presence of equivalent amounts of FK than it was in its 
absence. When the cells were preincubated with 10 Ilg CsA. 
the absolute uptake of [JHJ CsA was reduced in all cases 
relative to panels A and C. suggesting that some of the 
cellular CsA binding sites are taken up by unlabeled CsA. 
However. even under these conditions. inclusion of FK in the 
medium was able to induce a higher [lHJ CsA uptake (Fig 3. 
panels A. B. and C) compared with unstimulated cells. 
Conditions for these experiments were identical to those for 
the experiments in Fig 3. except that preincubations with 10 
Ilg CsA and I Ilg FK/ml of medium were for 72 hours. 
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Again. the uptake of IJH) CsA is enhanced when the 
Incuballons contain amounts of FK equivalent to the 
amounts of IlH) CsA at each point. 
DISCUSSION 
Cyclosporlne and FKS06 share a remarkable array of prop-
ertIes despite the obvious differences in their molecular 
structures. Although the immunosuppressive effects of 
FKS06 are several hundredfold greater than those of cyclo-
sporine A. the mechanism of immunosuppression of the two 
drugs is the same. i.e .• blockage of interleukin release. This 
report delineates further similarities between the two drugs. 
Both drugs exhibit saturation kinetics of binding to human 
peripheral blood lymphocytes. and both apparently bind to 
the same intracellular protein. I r it is indeed the same protein 
that both the drugs are bound to. the question of whether 
separate binding sites are involved in this process must be 
investigated. Our results also demonstrate that human 
peripheral blood lymphocytes exposed to FKS06 are able to 
take up more cyclosporine relative to cells that are not 
similarly exposed. Their sensitivity to cvclosporme in terms 
of MLC and primed lymphocyte tests is also increased. This 
evidence suggests that binding of one drug. FKS06. appears 
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to modify the cellular response to another drug. cyclosporine. 
resulting in a greater uptake of cyclosporine by the cell. 
CONCLUSIONS 
The binding and kinetics of uptake of FK506 by human 
peripheral blood lymphocyte exhibit a saturable process. 
with saturation occurring at a concentration of approxi. 
mately O.S I'M of the drug. 
Skatchard analysis of binding data (Fig I) indicates two 
distinct classes of binding sites for FKS06: (I) Kd - 3.9 := 
I.S x 1O-'M. high affinity. and (2) Kd - 5.2 :!: 0.8 x 10-6M. 
low affinity. 
Intracellularly. both drugs appear to bind to a common 
protein with an apparent molecular weight of IS.OOO to 
19.000 dalton. 
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